Asher Bio has launched with $55m in series A financing to commercialise research partially conducted at WashU and Leiden.

Parkwalk Advisors has returned to back a $46m round for PhoreMost, weeks after the latter’s spinout Neophore attracted $21m in a series B.

The lab-grown meat developer has picked up $47m in its series A round thanks to commitments from investors including Section 32 and Agronomics.

Peking University-backed Yanchuang Capital co-led a series A round for Innoforce Pharmaceuticals that will support the construction of manufacturing facilities.

Cash Capital has participated in a $70m series B round for Shanghai ZhenGe Biotechnology, bringing the company’s total financing to $125m.

VIB’s antiviral treatment developer has closed its series A round following a $22.6m extension backed by the research institute, V-Bio Ventures and Vives Inter-University Fund.

Forbion and Gilde Healthcare have co-led a $53m series B round for Dundee spinout Amphista, which is working on targeted protein degradation technology.

UF Innovate Ventures has contributed to a series B round for StrideBio, partially based on research into gene therapies at University of Florida.

The money will fund the progress of the University of London-linked precision medicine developer's lead drug candidate into the clinic.

The regenerative therapy developer is based on research at University of Torino and has raised capital from returning backer V-Bio Ventures.